))
Lorlatinib shrinks rare brain tumour in child after the standard of care fails.
Manage episode 337510354 series 3382249
内容由Andrew Scarborough提供。所有播客内容（包括剧集、图形和播客描述）均由 Andrew Scarborough 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
8-year-old Deliah Sitorius had been fighting a rare brain cancer for almost a year with chemotherapy . Unfortunately this was unsuccessful and she stopped treatment immediately. Deliah was given hope after her mother discovered the tumour has a rare mutation often seen in lung cancer. Since applying a more targeted, personalised approach using a drug called Lorlatinib the tumour has been shrinking.
Loratinib is a third generation ALK ROS1 tyosine kinase inhibitor, specifically designed to overcome known ALK resistance mutations. It is able to penetrate the blood brain barrier and more recently we have seen paediatric brain cancer patients who are responding very well to the drug.
21集单集
分享
